Search Results - "Szarek, M."

Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study by GOLDSTEIN, L. B, AMARENCO, P, SZAREK, M, CALLAHAN, A, HENNERICI, M, SILLESEN, H, ZIVIN, J. A, WELCH, K. M. A

“…In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study, atorvastatin 80 mg/day reduced the risk of stroke in patients with…”
Get full text

Activin A target genes are differentially expressed between normal and neoplastic adult human testes: clues to gonocyte fate choice by Szarek, M., Bergmann, M., Konrad, L., Schuppe, H.‐C., Kliesch, S., Hedger, M. P., Loveland, K. L.

“…Background Human testicular germ cell tumours (TGCT) arise from germ cell neoplasia in situ (GCNIS) cells that originate from foetal germ cell precursors…”
Get full text

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS) by Charlton-Menys, V, Betteridge, D. J, Colhoun, H, Fuller, J, France, M, Hitman, G. A, Livingstone, S. J, Neil, H. A. W, Newman, C. B, Szarek, M, DeMicco, D. A, Durrington, P. N

“…Aims/hypothesis Controversy surrounds whether the ratio of apolipoprotein B (ApoB) to apolipoprotein A-I (ApoA-I) is the best lipoprotein discriminator of CHD…”
Get full text

Relation of Characteristics of Metabolic Syndrome to Short-Term Prognosis and Effects of Intensive Statin Therapy After Acute Coronary Syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial by Schwartz, Gregory G, Olsson, Anders G, Szarek, Michael, Sasiela, William J

“…OBJECTIVE:--We examined relations between characteristics of the metabolic syndrome, early cardiovascular risk, and effect of early, intensive statin therapy…”
Get full text

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS) by Hitman, G. A., Colhoun, H., Newman, C., Szarek, M., Betteridge, D. J., Durrington, P. N., Fuller, J., Livingstone, S., Neil, H. A. W.

“…Aims  Patients with Type 2 diabetes have an elevated risk of stroke. The role of lipid levels and diabetes‐specific factors in risk prediction of stroke is…”
Get full text

Cardiovascular risk factors and disease mortality among asian american subgroups by Aggarwal, R, Wadhera, R, Szarek, M, Bhatt, D

“…Abstract Background Asian Americans are the fastest growing racial group in the United States. Although Asian subgroups have distinct cardiovascular (CV) risk…”
Get full text

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS) by Charlton-Menys, V., Betteridge, D. J., Colhoun, H., Fuller, J., France, M., Hitman, G. A., Livingstone, S. J., Neil, H. A. W., Newman, C. B., Szarek, M., DeMicco, D. A., Durrington, P. N.

Get full text

Efficacy of sotagliflozin by diabetes duration: a secondary analysis of SCORED by Aggarwal, R, Bhatt, D, Szarek, M, Davies, M, Banks, P, Pitt, B, Steg, G

“…Abstract Background Sotagliflozin is a sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibitor. SCORED randomized patients with type 2 diabetes (DM) and high…”
Get full text

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure by Bhatt, Deepak L, Szarek, Michael, Steg, P. Gabriel, Cannon, Christopher P, Leiter, Lawrence A, McGuire, Darren K, Lewis, Julia B, Riddle, Matthew C, Voors, Adriaan A, Metra, Marco, Lund, Lars H, Komajda, Michel, Testani, Jeffrey M, Wilcox, Christopher S, Ponikowski, Piotr, Lopes, Renato D, Verma, Subodh, Lapuerta, Pablo, Pitt, Bertram

“…Patients with diabetes and recent worsening heart failure that had led to hospitalization were randomly assigned to receive sotagliflozin or placebo. At a…”
Get full text

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome by Schwartz, Gregory G, Steg, P. Gabriel, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Diaz, Rafael, Edelberg, Jay M, Goodman, Shaun G, Hanotin, Corinne, Harrington, Robert A, Jukema, J. Wouter, Lecorps, Guillaume, Mahaffey, Kenneth W, Moryusef, Angèle, Pordy, Robert, Quintero, Kirby, Roe, Matthew T, Sasiela, William J, Tamby, Jean-François, Tricoci, Pierluigi, White, Harvey D, Zeiher, Andreas M

“…Among patients who had had an acute coronary syndrome, the risk of death from coronary heart disease, nonfatal myocardial infarction, stroke, or unstable…”
Get full text

Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF by Szarek, M, Bhatt, D, Steg, P G, Davies, M J, Pitt, B

“…Abstract Background In SOLOIST-WHF, the dual SGLT1 and SGLT2 inhibitor sotagliflozin (SOTA) reduced primary endpoint events – total occurrences of…”
Get full text

VALIDATION OF A BRIEF SCREENING MEASURE OF ENVIRONMENTAL CHEMICAL SENSITIVITY: THE CHEMICAL ODOR INTOLERANCE INDEX by Szarek, Michael J., Bell, Iris R., Schwartz, Gary E.

“…The development and validation of a brief self-report screening measure of environmental chemical sensitivity, the Chemical Odor Intolerance Index (CII), is…”
Get full text

Effects of High-Dose Atorvastatin in Patients ≥65 Years of Age With Acute Coronary Syndrome (from the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering [MIRACL] Study) by Olsson, Anders G., MD, PhD, Schwartz, Gregory G., MD, PhD, Szarek, Michael, MS, Luo, Don, PhD, Jamieson, Michael J., MD

“…After acute coronary syndromes (ACSs), older patients are particularly susceptible to early complications, including death and recurrent ACS. Lipid management…”
Get full text

Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial by Steg, Philippe Gabriel, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Brégeault, Marie-France, Dalby, Anthony J, Diaz, Rafael, Edelberg, Jay M, Goodman, Shaun G, Hanotin, Corinne, Harrington, Robert A, Jukema, J Wouter, Lecorps, Guillaume, Mahaffey, Kenneth W, Moryusef, Angèle, Ostadal, Petr, Parkhomenko, Alexander, Pordy, Robert, Roe, Matthew T, Tricoci, Pierluigi, Vogel, Robert, White, Harvey D, Zeiher, Andreas M, Schwartz, Gregory G

“…BACKGROUND:Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events,…”
Get full text

Plasma levels of human growth differentiation factor 15 (GDF-15) and their effect of alirocumab on major adverse cardiovascular events and all-cause death after acute coronary syndrome by Jukema, J, Van Neer, N J, Szarek, M, Cobbaert, C, Bittner, V A, Schwertfeger, M, Bhatt, D L, Fazio, S, Garon, G, Goodman, S G, Harrington, R A, Steg, P G, Stevanovic, I, White, H D, Schwartz, G G

“…Abstract Background Human growth differentiation factor 15 (GDF-15) is a stress response cytokine of the transforming growth factor-β superfamily with roles in…”
Get full text

Relation of apolipoprotein C3 to risk of major adverse cardiovascular events and death after acute coronary syndrome on a background of optimized statin treatment by Schwartz, G G, Reijnders, E, Szarek, M, Jukema, W J, Bhatt, D L, Bittner, V A, Fazio, S, Garon, G, Goodman, S G, Harrington, R A, Stevanovic, I, White, H D, Cobbaert, C, Steg, P G

“…Abstract Background Apolipoprotein C3 (ApoC3), a component of triglyceride-rich lipoproteins and some low-density lipoprotein and high-density lipoprotein…”
Get full text

Evaluation of the benefit of rivaroxaban on VOYAGER PAD primary composite of limb, heart and brain outcomes using the global rank and win ratio methods by Bonaca, M, Debus, S, Nehler, M, Anand, S, Patel, M, Pap, A F, Deng, H, Hodge, S, Szarek, M, Haskell, L, Muehlhofer, E, Berkowitz, S, Bauersachs, R

“…Abstract Background/Introduction The VOYAGER PAD trial demonstrated that rivaroxaban 2.5 mg twice daily added to background antiplatelet therapy reduced a…”
Get full text

Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES by Szarek, M, Steg, P G, Jukema, J W, Reijders, E, Schwertfeger, M, Bhatt, D, Bittner, V, Diaz, R, Fazio, S, Garon, G, Goodman, S G, Harrington, R A, White, H, Cobbaert, C, Schwartz, G G

“…Abstract Background Lipoprotein (a) (Lp(a)) is a risk factor for incident and recurrent ischemic cardiovascular (CV) events and may modify the benefit of PCSK9…”
Get full text

Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT by Szarek, M, Bhatt, D, Miller, M, Steg, P G, Brinton, E A, Jacobson, T A, Tardif, J C, Ballantyne, C M, Ketchum, S B, Pineda, A L, Dunbar, R L, Siri-Tarino, P W, Mason, R P

“…Abstract Background In REDUCE-IT, icosapent ethyl (IPE) reduced major adverse cardiovascular (CV) events (MACE) relative to placebo (PBO) in 8179…”
Get full text

HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events by Barter, Philip, Gotto, Antonio M, LaRosa, John C, Maroni, Jaman, Szarek, Michael, Grundy, Scott M, Kastelein, John J.P, Bittner, Vera, Fruchart, Jean-Charles

“…In a post hoc analysis of the Treating to New Targets study, high-density lipoprotein cholesterol levels in patients receiving statin therapy were shown to be…”
Get full text